Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy.
Daimantas MilonasA LaenenZ VenclovasL JaruseviciusG DevosS JoniauPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
In patients who underwent RP for HRPCa, persistent PSA was associated with poor oncological outcomes. Early SRT ± ADT resulted in significantly improved CSS and OS in men with persistent PSA comparing with early androgen deprivation monotherapy.
Keyphrases
- radical prostatectomy
- prostate cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- stem cells
- prognostic factors
- clinical trial
- metabolic syndrome
- peritoneal dialysis
- randomized controlled trial
- adipose tissue
- mesenchymal stem cells
- open label
- weight loss
- patient reported outcomes